BTK inhibitor ibrutinib is cytotoxic to myeloma and...

Cellular Signalling 2013 Vol. 25; Iss. 1

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

Stuart A. Rushworth, Kristian M. Bowles, Lawrence N. Barrera, Megan Y. Murray, Lyubov Zaitseva, David J. MacEwan
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
25
Year:
2013
Language:
english
DOI:
10.1016/j.cellsig.2012.09.008
File:
PDF, 764 KB
english, 2013
Conversion to is in progress
Conversion to is failed